<DOC>
	<DOCNO>NCT00841789</DOCNO>
	<brief_summary>The purpose study determine whether Etanercept ( Enbrel ) use conjunction IVIG aspirin , improve treatment response IVIG patient Kawasaki Disease . Funding Source- FDA/OOPD</brief_summary>
	<brief_title>Etanercept Kawasaki Disease</brief_title>
	<detailed_description>Kawasaki Disease ( KD ) potentially life threaten acute vasculitis child predilection involvement coronary artery . Aspirin Intravenous gamma globulin ( IVIG ) principally use treatment symptom Kawasaki Disease . Aspirin reduce inflammation platelet formation , effect attenuate development coronary abnormality . Although IVIG reduce inflammation prevalence coronary artery abnormality , relatively high failure rate 23-30 % , warrant new treatment method Kawasaki Disease . We propose placebo control double blind randomize study determine etanercept 0.8 mg/kg subcutaneously ( max 25 mg ) give three time weekly interval start initial diagnosis safe patient population successful adjunct therapy IVIG reduce incidence persistent recurrent fever .</detailed_description>
	<mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Male Age 2 month 20 year age Female Age 2 month 11 year age Provision Parental Consent Kawasaki Disease Presentation Laboratory Criteria : Any laboratory toxicity , time screen visit time study opinion Investigator would preclude participation study : 1 . Platelet count &lt; 100,000/mm3 2 . WBC count &lt; 3,000 cells/mm3 3 . Hemoglobin , hematocrit , red blood cell count outside 30 % upper low limit normal Lab Subject currently enrol another investigational device drug trial ( ) , subject receive investigational agent ( ) within 28 day baseline visit . Female subject diagnose KD 12 year age old . Subjects know hypersensitivity Enbrel component know antibody etanercept Prior concurrent cyclophosphamide therapy Prior treatment TNF alpha antagonist steroid within 48 hour prior initiation IVIG Concurrent sulfasalazine therapy Active severe infection within 4 week screen visit , screen baseline visit . SLE , history multiple sclerosis , transverse myelitis , optic neuritis , chronic seizure disorder Known HIVpositive status know history immunosuppressing disease . Any mycobacterial disease high risk factor tuberculosis , family member TB take INH Untreated Lyme disease Severe comorbidities ( diabetes mellitus require insulin , CHF severity , MI , CVA TIA within 3 month screen visit , unstable angina pectoris , uncontrolled hypertension ( sit systolic BP &gt; 160 diastolic BP &gt; 100 mm Hg ) , oxygendependent severe pulmonary disease , history cancer within 5 year [ resect cutaneous basal squamous cell carcinoma situ cervical cancer ] ) Exposure hepatitis B hepatitis C high risk factor intravenous drug abuse patient 's mother , history jaundice ( neonatal jaundice ) . SLE , history multiple sclerosis , transverse myelitis , optic neuritis chronic seizure disorder . Use live vaccine ( Measles Mumps Rubella Varicella ) 30 day prior study . Any condition judge patient 's physician cause clinical trial detrimental patient History noncompliance therapy Must receive immunosuppressive agent least three month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Etanercept</keyword>
</DOC>